Five Best And Worst Performing Mid-Cap Stocks In Q4 2022
Mid-cap stocks are proving to be an attractive investment option over the past few years. In fact, the S&P MidCap 400 index has performed better t
Stay updated with breaking news from Nasdaq Pcvx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mid-cap stocks are proving to be an attractive investment option over the past few years. In fact, the S&P MidCap 400 index has performed better t
Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses. In recent years, mid-cap stocks have o
SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) VP Jeff Fairman sold 4,112 shares of Vaxcyte stock in a transaction on Friday, May 20th. The stock was sold at an average price of $25.50, for a total transaction of $104,856.00. Following the transaction, the vice president now directly owns 321,227 shares in the company, valued at $8,191,288.50. […]
Vaxcyte (NASDAQ:PCVX – Get Rating) issued its earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05), MarketWatch Earnings reports. Shares of NASDAQ PCVX traded up $0.04 during midday trading on Tuesday, hitting $21.45. 27,829 shares of the stock traded hands, compared to […]